Merck & Company Inc (MRK) - Total Liabilities
Based on the latest financial reports, Merck & Company Inc (MRK) has total liabilities worth $87.82 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MRK long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Merck & Company Inc - Total Liabilities Trend (1985–2025)
This chart illustrates how Merck & Company Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see MRK total assets.
Merck & Company Inc Competitors by Total Liabilities
The table below lists competitors of Merck & Company Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Agricultural Bank of China Ltd Class A
SHG:601288
|
China | CN¥47.73 Trillion |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
China | CN¥51.42 Trillion |
|
Morgan Stanley
NYSE:MS
|
USA | $1.47 Trillion |
|
Netflix Inc
NASDAQ:NFLX
|
USA | $28.98 Billion |
|
Cisco Systems Inc
NASDAQ:CSCO
|
USA | $75.65 Billion |
|
Palo Alto Networks Inc
NASDAQ:PANW
|
USA | $18.60 Billion |
|
The Home Depot Inc
NYSE:HD
|
USA | $94.16 Billion |
|
Philip Morris International Inc
NYSE:PM
|
USA | $74.93 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Merck & Company Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See MRK net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Merck & Company Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Merck & Company Inc (1985–2025)
The table below shows the annual total liabilities of Merck & Company Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $84.20 Billion | +19.04% |
| 2024-12-31 | $70.73 Billion | +2.45% |
| 2023-12-31 | $69.04 Billion | +9.41% |
| 2022-12-31 | $63.10 Billion | -6.43% |
| 2021-12-31 | $67.44 Billion | +1.89% |
| 2020-12-31 | $66.18 Billion | +13.34% |
| 2019-12-31 | $58.40 Billion | +4.74% |
| 2018-12-31 | $55.76 Billion | +4.60% |
| 2017-12-31 | $53.30 Billion | -3.21% |
| 2016-12-31 | $55.07 Billion | -3.23% |
| 2015-12-31 | $56.91 Billion | +15.26% |
| 2014-12-31 | $49.38 Billion | -7.40% |
| 2013-12-31 | $53.32 Billion | +5.23% |
| 2012-12-31 | $50.67 Billion | +5.16% |
| 2011-12-31 | $48.19 Billion | -1.62% |
| 2010-12-31 | $48.98 Billion | -3.65% |
| 2009-12-31 | $50.83 Billion | +95.28% |
| 2008-12-31 | $26.03 Billion | -6.23% |
| 2007-12-31 | $27.76 Billion | +12.82% |
| 2006-12-31 | $24.60 Billion | +0.59% |
| 2005-12-31 | $24.46 Billion | +6.92% |
| 2004-12-31 | $22.88 Billion | +8.45% |
| 2003-12-31 | $21.10 Billion | -13.66% |
| 2002-12-31 | $24.43 Billion | +5.61% |
| 2001-12-31 | $23.13 Billion | +15.34% |
| 2000-12-31 | $20.06 Billion | +5.94% |
| 1999-12-31 | $18.93 Billion | +23.37% |
| 1998-12-31 | $15.35 Billion | +28.15% |
| 1997-12-31 | $11.98 Billion | +19.60% |
| 1996-12-31 | $10.01 Billion | +2.07% |
| 1995-12-31 | $9.81 Billion | +3.17% |
| 1994-12-31 | $9.51 Billion | +8.53% |
| 1993-12-31 | $8.76 Billion | +60.58% |
| 1992-12-31 | $5.46 Billion | +36.82% |
| 1991-12-31 | $3.99 Billion | +9.37% |
| 1990-12-31 | $3.65 Billion | +33.74% |
| 1989-12-31 | $2.73 Billion | -16.67% |
| 1988-12-31 | $3.27 Billion | -8.18% |
| 1987-12-31 | $3.56 Billion | +40.50% |
| 1986-12-31 | $2.54 Billion | +11.81% |
| 1985-12-31 | $2.27 Billion | -- |
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more